US equities
|
META
$632.24
▼-1.62%
TSLA
$387.93
▲+4.22%
SPCX
$146.70
▼-0.54%
MU
$892.38
▲+1.69%
NVDA
$214.28
▲+1.57%
AAPL
$343.69
▼-1.16%
SNDK
$1,263.97
▲+2.10%
NU
$11.82
▼-22.00%
META
$632.24
▼-1.62%
TSLA
$387.93
▲+4.22%
SPCX
$146.70
▼-0.54%
MU
$892.38
▲+1.69%
NVDA
$214.28
▲+1.57%
AAPL
$343.69
▼-1.16%
SNDK
$1,263.97
▲+2.10%
NU
$11.82
▼-22.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Veraxa Biotech AG - Ordinary Shares
(NQ:
VRXA
)
0.9999
-0.0001 (-0.01%)
Delayed Quote
Updated: 9:34 AM EDT, Oct 26, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Veraxa Biotech AG - Ordinary Shares
< Previous
1
2
3
Next >
BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Aims for Greater Precision in Cancer Therapy
October 21, 2026
Via
Investor Brand Network
VERAXA Biotech AG (NASDAQ: VRXA) Expands Human-Relevant Testing Strategy to Advance Antibody-Based Cancer Pipeline
October 20, 2026
Via
Investor Brand Network
Topics
Animal Testing
BillionDollarBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Presents First In Vivo Proof-of-Concept Data for BiTAC-ADC Platform at World ADC Congress
October 13, 2026
Via
Investor Brand Network
VERAXA Biotech Presents in vivo Proof-of-Concept Data for BiTAC®-ADC Technology at World ADC Congress
October 13, 2026
In vivo data confirm activation of prodrug payload inside tumor cells following systemic administration of BiTAC-ADC molecules leading to potent anti-tumor activity
From
Veraxa Biotech AG
Via
GlobeNewswire
BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Advances FDA-Aligned Methods to Reduce Animal Testing
October 07, 2026
Via
Investor Brand Network
Topics
Animal Testing
VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy
October 07, 2026
Consistent Use of New Approach Methodologies (NAMs) to Potentially Accelerate BiTAC® Oncology Pipeline and Significantly Reduce Animal Testing Needs
From
Veraxa Biotech AG
Via
GlobeNewswire
InvestorNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Moves VXA-222 Bispecific ADC to Next Development Stage
September 29, 2026
Via
Investor Brand Network
Topics
Intellectual Property
BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Advances Oncology Pipeline Following Nasdaq Listing as Xlife Sciences (SIX: XLS) Reports First-Half Progress
September 24, 2026
Via
Investor Brand Network
Topics
Intellectual Property
VERAXA Biotech AG (NASDAQ: VRXA) Builds Oncology Pipeline Around BiTAC Platform, Public-Market Story Enters Next Phase
September 21, 2026
Via
Investor Brand Network
VERAXA Biotech AG (NASDAQ: VRXA) Adds Capital Markets Veteran as CFO While Advancing BiTAC Oncology Pipeline
September 17, 2026
Via
Investor Brand Network
InvestorNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Developing Next-Gen Cancer Therapies with Dual-Targeting Approach
September 16, 2026
Via
Investor Brand Network
VERAXA Biotech AG (NASDAQ: VRXA) Building a New Approach to Precision Cancer Therapy
September 15, 2026
Via
Investor Brand Network
BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Bolsters Scientific Leadership Ahead of BiTAC(R) Clinical Development
September 10, 2026
Via
Investor Brand Network
These stocks are moving in today's session
↗
September 04, 2026
Via
Chartmill
NetworkNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Appoints Raju Willener as Chief Financial Officer
September 04, 2026
Via
Investor Brand Network
VERAXA Biotech Appoints Raju Willener as Chief Financial Officer
September 04, 2026
Mr. Willener brings more than three decades of global capital markets and corporate finance experience to support advancement of the Company’s pipeline of potential best-in-class therapies led by its...
From
Veraxa Biotech AG
Via
GlobeNewswire
VERAXA Biotech AG (NASDAQ: VRXA), Secarna Partnership Milestone Opens New Potential Market for Conjugation Technology
August 27, 2026
Via
Investor Brand Network
BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) and Secarna Report Positive Early Results From Antibody Oligonucleotide Collaboration
August 24, 2026
Via
Investor Brand Network
VERAXA Biotech AG (NASDAQ: VRXA) Advances VXA-222 Cancer Program Beyond Discovery Phase
August 24, 2026
Via
Investor Brand Network
Topics
Intellectual Property
VERAXA Biotech and Secarna Pharmaceuticals Achieve Research Milestone in Antibody Oligonucleotide Conjugate (AOC) Alliance
August 24, 2026
Successful in vitro proof-of-concept study demonstrates the potential to create novel antibody-oligonucleotide conjugates (AOCs) by combining both parties’ technologies and expertise
From
Veraxa Biotech AG
Via
GlobeNewswire
MissionIRNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Strengthens Clinical Development Path for Next-Gen Cancer Therapy
August 21, 2026
Via
Investor Brand Network
VERAXA Biotech AG (NASDAQ: VRXA) Builds Antibody-Based Cancer Pipeline Around Dual-Targeting Precision
August 21, 2026
Via
Investor Brand Network
Topics
Intellectual Property
InvestorNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Turns to AI to Advance Precision Oncology
August 18, 2026
Via
Investor Brand Network
Topics
Artificial Intelligence
MissionIRNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Turns to AI to Advance Precision Oncology
August 18, 2026
Via
Investor Brand Network
Topics
Artificial Intelligence
BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Builds Strategic Position in Antibody Therapeutics Market
August 07, 2026
Via
Investor Brand Network
VERAXA Biotech AG (NASDAQ: VRXA) Advances VXA-222 Cancer Program While Expanding Patent Portfolio for Next-Generation Antibody Technologies
August 05, 2026
Via
Investor Brand Network
Topics
Intellectual Property
VERAXA Biotech AG (NASDAQ: VRXA) Strengthens Scientific Leadership as New CSO Takes the Helm in Advancing BiTAC(R) Cancer Therapy Platform
July 29, 2026
Via
Investor Brand Network
InvestorNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Expands Patent Portfolio to Support Next-Generation Cancer Therapy Platforms
July 29, 2026
Via
Investor Brand Network
Topics
Intellectual Property
VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates
July 29, 2026
First BiTAC®-related patent applications filed in H1 2026 including patents covering composition of matter and proprietary payload platform, with additional patents secured in contributing technology...
From
Veraxa Biotech AG
Via
GlobeNewswire
MissionIRNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Shareholders Approve Corporate Governance, Financing Measures
July 27, 2026
Via
Investor Brand Network
< Previous
1
2
3
Next >
